$
5.460
+0.02(0.368%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.470
Open
5.440
VWAP
5.45
Vol
560.69K
Mkt Cap
1.23B
Low
5.440
Amount
3.06M
EV/EBITDA(TTM)
3.19
Total Shares
224.31M
EV
791.67M
EV/OCF(TTM)
4.43
P/S(TTM)
2.18
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
32.56M
+124.57%
-0.136
-2.86%
34.59M
-93%
0.096
-93.58%
3.34M
-76.88%
-0.184
-42.61%
Estimates Revision
The market is revising Upward the revenue expectations for CureVac N.V. (CVAC) for FY2025, with the revenue forecasts being adjusted by 8.63% over the past three months. During the same period, the stock price has changed by 57.35%.
Revenue Estimates for FY2025
Revise Upward
up Image
+8.63%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.88%
In Past 3 Month
Stock Price
Go Up
up Image
+57.35%
In Past 3 Month
5 Analyst Rating
down Image
-23.63% Downside
Wall Street analysts forecast CVAC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVAC is 4.17 USD with a low forecast of 2.00 USD and a high forecast of 5.50  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
4 Hold
1 Sell
Hold
down Image
-23.63% Downside
Current: 5.460
sliders
Low
2.00
Averages
4.17
High
5.50
UBS
Buy
to
Neutral
downgrade
$12
2025-06-26
Reason
UBS downgraded CureVac (CVAC) to Neutral from Buy with a price target of $5.50, down from $12. BioNTech (BNTX) announced the acquisition of CureVac for $5.46 per share, or a total equity value of $1.25B, the analyst tells investors in a research note.
Jefferies
Roger Song
Buy
to
Hold
downgrade
$7 -> $5
2025-06-12
Reason
Jefferies analyst Roger Song downgraded CureVac (CVAC) to Hold from Buy with a price target of $5, down from $7, after the company agreed to be acquired by BioNTech (BNTX). Under the terms of the agreement, each CureVac share will be exchanged for $5.46 in BioNTech shares, resulting in an implied aggregate equity value for CureVac of $1.25B.
BofA
Underperform
downgrade
$2
2025-05-21
Reason
BofA lowered the firm's price target on CureVac to $2 from $2.50 and keeps an Underperform rating on the shares. Q1 results highlighted the progression of the pipeline in early-stage clinical studies, but the firm sees work to be done to prove the value of the pipeline and awaits clarity on the patent dispute situation, the analyst tells investors.
JMP Securities
Roy Buchanan
Buy
Reiterates
$16
2025-02-14
Reason
JMP Securities
Roy Buchanan
Buy
Reiterates
$16
2024-09-16
Reason
JMP Securities
Roy Buchanan
Buy
Maintains
$18 → $16
2024-08-16
Reason

Valuation Metrics

The current forward P/E ratio for CureVac NV (CVAC.O) is -9.70, compared to its 5-year average forward P/E of -7.97. For a more detailed relative valuation and DCF analysis to assess CureVac NV 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.97
Current PE
-9.70
Overvalued PE
7.75
Undervalued PE
-23.69

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-10.38
Current EV/EBITDA
-6.84
Overvalued EV/EBITDA
3.78
Undervalued EV/EBITDA
-24.54

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
33.19
Current PS
14.27
Overvalued PS
78.33
Undervalued PS
-11.95

Financials

Annual
Quarterly
FY2025Q1
YoY :
-92.78%
893.00K
Total Revenue
FY2025Q1
YoY :
-25.58%
-54.73M
Operating Profit
FY2025Q1
YoY :
-26.18%
-52.08M
Net Income after Tax
FY2025Q1
YoY :
-25.81%
-0.23
EPS - Diluted
FY2025Q1
YoY :
-58.79%
-41.89M
Free Cash Flow
FY2025Q1
YoY :
-100.85%
2.02
Gross Profit Margin - %
FY2025Q1
27.34
FCF Margin - %
FY2025Q1
YoY :
+922.85%
-5.83K
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CVAC News & Events

Events Timeline

2025-06-12 (ET)
2025-06-12
12:52:09
CureVac downgraded to Market Perform from Outperform at Citizens JMP
select
2025-06-12
06:48:58
BioNTech to acquire CureVac in all-stock transaction
select
2025-05-20 (ET)
2025-05-20
07:23:14
CureVac reaffirms expected cash runway into 2028
select
Sign Up For More Events

News

4.0
06-26Benzinga
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
6.0
06-26Benzinga
UBS Downgrades CureVac to Neutral, Lowers Price Target to $5.5
8.5
06-20NASDAQ.COM
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Sign Up For More News

FAQ

arrow icon

What is CureVac NV (CVAC) stock price today?

The current price of CVAC is 5.46 USD — it has increased 0.37 % in the last trading day.

arrow icon

What is CureVac NV (CVAC)'s business?

arrow icon

What is the price predicton of CVAC Stock?

arrow icon

What is CureVac NV (CVAC)'s revenue for the last quarter?

arrow icon

What is CureVac NV (CVAC)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for CureVac NV (CVAC)'s fundamentals?

arrow icon

How many employees does CureVac NV (CVAC). have?

arrow icon

What is CureVac NV (CVAC) market cap?